HealthQuill Sanofi SA
Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.
Drugs Health Pharma

France’s Sanofi SA to acquire US-based Vigil Neuroscience for $470 million 

HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies.

Read More
Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate of worsening episodes in adults with moderate-to-severe asthma, according to a statement.
Drugs Health Pharma

Sanofi’s test drug to treat moderate-to-severe asthma fails to meet goals 

HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.

Read More
Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the French company will invest 300 million euros for a 16% equity.
Drugs Health Pharma

Sanofi to invest $324m in entity with Orano Med for radioligand therapy

Sanofi and Orano Med agreed to form a new entity, valued at 1.9 billion euros ($2.06 billion), to develop radioligand medicines and the.

Read More
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's immune system to attack red blood cells, for an upfront $825 million.
Drugs Health Pharma

Recordati buys Sanofi’s drug for autoimmune disease for $825 million

Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's.

Read More
French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply of the medicine.
Drugs Health Pharma

Sanofi to invest $1.4 billion to build new insulin plant in Frankfurt

French drugmaker Sanofi SA will build a 1.3 billion euro ($1.4 billion) insulin manufacturing facility in Germany’s Frankfurt to secure the long-term supply.

Read More